# Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

> **NCT05146154** · PHASE4 · WITHDRAWN · sponsor: **University of Illinois at Chicago**

## Conditions studied

- Obesity
- Critical Illness

## Interventions

- **DRUG:** Imipenem/Cilastatin/Relebactam 1.25g

## Key facts

- **NCT ID:** NCT05146154
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator is no longer at University of Illinois
- **Last updated:** 2024-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146154, "Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05146154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*